During his tenure of office as head of the FDA, Frank E. Young______.
A.
had a bitter argument with his colleagues over the overhaul of drug-approval policies
B.
played a leading role in reconstructing the FDA's policies
C.
made some efforts to overhaul drug-approval policies, but failed
D.
met many difficulties in releasing breakthrough drugs to the desperately iii patients